A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
The FDA accepted a supplemental biologics license application and granted priority review for Datroway for adults ...
The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
AstraZeneca & Daiichi Sankyo’s Datroway granted Priority Review in US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy: Cambridge ...
In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.
Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales. | Astellas surpassed ...
Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many ...
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.
DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...
Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...
The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...
The company has garnered FDA fast-track status and will soon start a controlled trial of its oncolytic virus with standard therapy.